Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 3 of a 4-Part Series

Featuring perspectives from Dr Antonio González-Martín, including the following topics: Introduction: Treatment-Related Second Cancers (0:00) Case: A woman in her mid 40s (gBRCA) who presents with ascites and is diagnosed with high-grade serous ovarian cancer (HGSOC) with extensive peritoneal disease — Lyndsay J Willmott, MD (12:37) Case: A woman in her early 40s (gBRCA1) with HGSOC who experienced cardiac arrest due to anaphylaxis during paclitaxel infusion as part of a neoadjuvant paclitaxel/carboplatin/bevacizumab regimen — Kellie E Schneider, MD (30:33) Case: A woman in her late 50s (gBRCA1) with HGSOC and pelvic node recurrence after perioperative paclitaxel/carboplatin and optimal interval debulking surgery — Karim ElSahwi, MD (39:45) Case: A woman in her late 50s (gBRCA1) with Stage IIIA ovarian cancer and elevated creatinine due to donor nephrectomy — Paul DiSilvestro, MD (43:05) Case: A woman in her early 60s with recurrent ovarian cancer after a chemotherapy and niraparib maintenance regimen and tumor treating fields with paclitaxel on a clinical trial — Gigi Chen, MD (46:28) Case: A woman in her late 50s with gBRCA1 and PMH of breast cancer and prophylactic bilateral salpingo-oophorectomy who develops recurrent peritoneal cancer and responds for 10 months to olaparib followed by chemotherapy followed by rucaparib and nivolumab on the TAPUR trial — John K Chan, MD (51:52) Journal Club (55:30) CME information and select publications